Does gliotoxin suppress immune defenses by inducing immune-cell apoptosis and inhibiting phagocyte and T-cell function?

Clinical evidence

Gliotoxin, a prominent virulence factor produced by Aspergillus fumigatus, acts as a potent immunosuppressant that systematically dismantles host defenses. Clinical and experimental models demonstrate that this toxin targets multiple arms of the immune system simultaneously, leading to profound immune evasion.

• Depletion of key leukocytes: Exposure to gliotoxin leads to a rapid, dose-dependent depletion of vital immune cells, including macrophages, monocytes, neutrophils, and T and B lymphocytes. At low-nanogram per milliliter concentrations, gliotoxin selectively blocks activation signals, while low-micromolar concentrations transition to direct cytotoxicity, physically depleting the active immune pool.
• Impairment of adaptive coordination: The functional suppression of T-helper and CD4 T-cells results in a drastic reduction in the secretion of critical coordinating cytokines, including interferon-gamma (IFN-γ) and interleukin-4 (IL-4). This suppression blocks the induction of alloreactive cytotoxic T lymphocytes (CTLs) and halts lymphocyte-mediated immune coordination.

Mechanistic explanations

Gliotoxin achieves systemic immunosuppression through precise, molecularly targeted pathways that disable both innate and adaptive cellular responses.

• Induction of apoptosis: Gliotoxin directly triggers the pro-apoptotic Bcl-2 family member Bak on the mitochondrial membrane. Active Bak causes mitochondrial outer membrane permeabilization, leading to a loss of mitochondrial membrane potential, the generation of reactive oxygen species (ROS), and the subsequent release of cytochrome c. This activates caspase-3-like proteases to execute caspase-dependent apoptosis.
• Survival signal blockade: In lymphoid cells, apoptosis is accelerated by the potent inhibition of the NF-κB survival pathway. By blocking the linear ubiquitin chain assembly complex (LUBAC) and preventing the proteasomal degradation of IκBα, gliotoxin blocks NF-κB nuclear translocation. This deprives leukocytes of critical anti-apoptotic transcriptional defenses.
• Phagocyte paralysis: In macrophages, gliotoxin prevents the generation of phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3], halting downstream Rac and Cdc42 signaling. This paralyzes actin-driven membrane ruffling and phagocytic cup formation. In neutrophils, it disrupts actin dynamics via cAMP- and arachidonic acid-dependent pathways, driving cell shrinkage and halting engulfment.
• Chemotaxis and oxidative burst inhibition: Gliotoxin blocks the synthesis of the chemoattractant leukotriene B4 (LTB4) by inhibiting leukotriene A4 hydrolase, preventing neutrophil recruitment. Furthermore, it targets the phagocyte NADPH oxidase (NOX2) complex; its reactive disulfide bridge prevents the phosphorylation and membrane translocation of cytosolic subunits (p47phox, p67phox, and p40phox), disabling the oxidative burst.
• T-cell receptor disruption: Beyond NF-κB inhibition, gliotoxin impairs early T-cell receptor (TCR) activation events, including inositol phosphate production, cell adhesion, and conjugate formation between CTLs and target cells, while also blocking granule exocytosis.

Bottom line

Gliotoxin suppresses immune defenses by inducing Bak-dependent, NF-κB-inhibited apoptosis in leukocytes, while simultaneously paralyzing phagocytes through the blockade of PtdIns(3,4,5)P3 and NADPH oxidase assembly, and disabling T-cells via LUBAC and TCR signaling disruption.